| 特集名 | 肝炎のインターフェロン治療 -- 総まとめ | |
|---|---|---|
| 題名 | C型肝炎のインターフェロン治療 (1) C型慢性肝炎治療のインターフェロン投与法と効果 | |
| 発刊年月 | 2000年 10月 | |
| 著者 | 松嶋 喬 | 市立函館病院消化器科 |
| 著者 | 狩野 吉康 | 札幌厚生病院消化器科 |
| 著者 | 豊田 成司 | 札幌厚生病院消化器科 |
| 【 要旨 】 | C型慢性肝炎に対する規定の範囲内の用法，用量によるIFN治療の著効率は30％程度である．著効率を上昇させる対策としては，長期投与法，IFN-β・1日2分割投与法が考えられている．IFN-β・3MU・1日2分割投与4週後，IFN-α・週3回，計24週投与の著効率は高率であった．IFN-β・1日2分割投与中のslL－2R,IL-6,ALTは上昇した．これらの成績は，著効率上昇の手段としてIFNと免疫調整剤との併用療法の有用性を示唆している．IFN長期投与法の著効率は上昇し，初回治療で非著効例が再投与により著効となることもある．C型慢性肝炎に対するIFN治療は症例ごとに用法，用量を変更して対応することが重要である． | |
| Theme | Interferon Therapy for Viral Hepatitis : an Update Handbook | |
|---|---|---|
| Title | Efficacy of Interferon Treatment for Patients with Chronic Hepatitis C | |
| Author | Takashi Matsushima | Hakodate Municipal Hospital |
| Author | Yoshiyasu Karino | Sapporo Kosei Hospital |
| Author | Joji Toyota | Sapporo Kosei Hospital |
| [ Summary ] | In cases of chronic hepatitis C, the goal of treatment, defined as complete response (CR), normal alanine aminotransferase levels and undetectable serum hepatitis C virus-RNA levels 6 months after therapy were achieved in approximately 30% of patients on the standard IFN schedule. IFN is known to possess both antiviral and immunomodulatory effects. We analysed 18 chronic hepatitis C patients undergoing combination therapy with IFN-beta and IFN-alpha (3MU of IFN-beta administration twice daily for 4 weeks, followed by IFN-alpha three times a week for 20 weeks) CR was observed in 14 cases(77.8%). Serum IR-2R, IL-6 and alanine aminotransferase levels increased in all the patients after 4 weeks of IFN-beta therapy. This data suggest the host immune response may be important in determining the outcome of IFN therapy for chronic HCV infections. When patients who were TR to initial treatment were retreated with IFN for 6 months, 15.4% had a CR. CR was frequently found in patients with HCV genotype 2 or low viral loads. Additional clinical trials have been conducted to evaluate alternative treatment modalities for chronic hepatitis C, including longer IFN treatment duration, i.e., 12 to 18 months. |
|